Net product sales consist of the following: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended
September 30, | | Nine Months Ended September 30, | | (In millions) | | | 2024 | | 2023 | | 2024 | | 2023 | EYLEA HD® | U.S. | | $ | 392.3 | | | $ | 42.7 | | | $ | 896.5 | | | $ | 42.7 | | EYLEA® | U.S. | | 1,144.6 | | | 1,448.2 | | | 3,576.7 | | | 4,382.1 | | | Total EYLEA HD and EYLEA | U.S. | | 1,536.9 | | | 1,490.9 | | | 4,473.2 | | | 4,424.8 | | Libtayo® | U.S. | | 194.5 | | | 144.1 | | | 536.1 | | | 384.0 | | Libtayo | Rest of world | | 94.1 | | | 88.3 | | | 313.8 | | | 235.3 | | Total Libtayo | Global | | 288.6 | | | 232.4 | | | 849.9 | | | 619.3 | | Praluent® | U.S. | | 52.9 | | | 40.4 | | | 179.0 | | | 121.1 | | Evkeeza® | U.S. | | 32.4 | | | 19.1 | | | 87.6 | | | 53.3 | | Inmazeb® | Global | | 35.6 | | | 3.3 | | | 36.6 | | | 7.7 | | | | | $ | 1,946.4 | | | $ | 1,786.1 | | | $ | 5,626.3 | | | $ | 5,226.2 | |
Amounts recognized in the Company's Statements of Operations in connection with its Sanofi collaboration are as follows: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Statement of Operations Classification | | Three Months Ended September 30, | | Nine Months Ended September 30, | | (In millions) | | | 2024 | | 2023 | | 2024 | | 2023 | Regeneron's share of profits | | Collaboration revenue | | $ | 1,088.3 | | | $ | 863.0 | | | $ | 2,880.6 | | | $ | 2,250.6 | | Sales-based milestones earned | | Collaboration revenue | | $ | — | | | $ | 50.0 | | | $ | — | | | $ | 50.0 | | | Reimbursement for manufacturing of commercial supplies | | Collaboration revenue | | $ | 175.1 | | | $ | 151.5 | | | $ | 438.2 | | | $ | 506.0 | | | Regeneron's obligation for its share of Sanofi R&D expenses, net of reimbursement of R&D expenses | | (R&D expense) | | $ | (7.8) | | | $ | (25.8) | | | $ | (35.5) | | | $ | (66.7) | | | Reimbursement of commercialization-related expenses | | Reduction of SG&A expense | | $ | 169.0 | | | $ | 135.5 | | | $ | 459.3 | | | $ | 384.0 | |
Amounts recognized in the Company's Statements of Operations in connection with its Bayer collaboration are as follows: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Statement of Operations Classification | | Three Months Ended September 30, | | Nine Months Ended September 30, | | (In millions) | | | 2024 | | 2023 | | 2024 | | 2023 | Regeneron's share of profits | | Collaboration revenue | | $ | 367.6 | | | $ | 349.9 | | | $ | 1,054.5 | | | $ | 1,031.0 | | | Reimbursement for manufacturing of ex-U.S. commercial supplies | | Collaboration revenue | | $ | 23.2 | | | $ | 27.2 | | | $ | 67.4 | | | $ | 79.7 | | | Regeneron's obligation for its share of Bayer R&D expenses, net of reimbursement of R&D expenses | | (R&D expense) | | $ | (11.8) | | | $ | (9.7) | | | $ | (35.2) | | | $ | (35.1) | |
Amounts recognized in the Company's Statements of Operations in connection with its Roche collaboration are as follows: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Statement of Operations Classification | | Three Months Ended September 30, | | Nine Months Ended
September 30, | | (In millions) | | | 2024 | | 2023 | | 2024 | | 2023 | Global gross profits earned in connection with sales of Ronapreve | | Collaboration revenue | | $ | 0.5 | | | $ | — | | | $ | 1.4 | | | $ | 222.2 | | Other | | Collaboration revenue | | $ | — | | | $ | (5.7) | | | $ | — | | | $ | (9.5) | |
|